TYPE 2 DIABETES MELLITUS AND SUBCLINICAL HYPOTHYROIDISM: FOCUSING ON THE ROLE OF CHOLECALCIFEROL
DOI:
https://doi.org/10.21856/j-PEP.2019.2.07Keywords:
type 2 diabetes mellitus, subclinical hypothyroidism, vitamin DAbstract
Background. Vitamin D deficiency has been associated with both type 2 diabetes mellitus (DM) and thyroid autoimmune disorders. The association of vitamin D with type DM and subclinical hypothyroidism (SH) has not been investigated. Aim of the study is to explore the putative association between type 2 DM and SH focusing on the role of 25-hydroxyvitamin D [25(OH)D]. Materials and methods. Study population included 65 type 2 DM patients, 35 patients with type 2 DM and SH and 50 healthy controls. To explore the potential association between 25(OH)D and SH while controlling for potential confounders-namely, age, gender, body mass index, and presence of type 2 DM-multivariate logistic regression analyses were undertaken. Results. Patients with type 2 DM and with type 2 and SH had significantly lower 25(OH)D and higher TSH and TPOAb titres compared to controls. The prevalence of vitamin D deficiency/insufficiency was significantly higher in patients with type 2 DM (92.3%), type 2 and SH (97.1%) compared to controls (86.0%). Multivariable logistic regression analyses suggested that type 2 DM and 25(OH)D levels were significantly associated with the presence of SH. Conclusions. In population of patients with type 2 and SH with a high prevalence of vitamin D deficiency/insufficiency, it was shown that type 2 DM and vitamin D were associated with SH.
References
Cutoto M, Pizzorni C, Sulli A. Autoimmun Rev 2011; 11 (2): 84-87. https://doi.org/10.1016/j.autrev.2011.08.003.
Xuan Y, Zhao HY, Liu JM. J Diabetes 2013;5(3): 261-267. https://doi.org/10.1111/1753-0407.12024.
Diez JJ, Iglesias P. Diabetic Med 2012; 29 (12): 1510-1514. https://doi.org/10.1111/j.1464-1491.2012.03687.x.
Gronich N, Deftereos SN, Lavi I, et al. Diabetes Care 2015; 38 (9): 1657-1664. https://doi.org/10.2337/dc14-2515.
Duntas LH, Orgiazzi J, Brabant G. Clin Endocrinol 2011; 75 (1): 1-9. https://doi.org/10.1111/j.1365-2265.2011.04029.x.
Mandarino NR, Junior F, Salgado JV, et al. Open Cardiovasc Med J 2015;9: 40-49. https://doi.org/10.2174/1874192401509010040.
Alam U, Arul-Devah V, Javed S, Malik RA. Diabetes Ther 2016;7(1): 11-26. https://doi.org/10.1007/s13300-016-0159-x.
Zoppini G, Galletti A, Targher G, et al. BMJ Open Diabetes Res Care 2015; 3 (1): e000058. https://doi.org/10.1136/bmjdrc-2014-000058.
Takiishi T, Gysemans C, Bouillon R, Mathieu C. Endocrinol Metab Clin North Am 2010; 39 (2): 419-446. https://doi.org/10.1016/j.ecl.2010.02.013.
Kivity S, Agmon-Levin N, Zisappl M, et al. Cell Mol Immunol 2011; 8 (3): 243-247. https://doi.org/10.1038/cmi.2010.73.
Garber JR, Cobin RH, Gharib H, et al. Endocr Pract 2012; 11: 1-207. https://doi.org/10.1089/thy.2012.0205.
Pludowski P, Grant WB, Bhattoa HP, et al. Int J Endocrinol 2014;2014: 589587. https://doi.org/10.1155/2014/589587.
Yilmaz H, Cakmak M, Darcin T, et al. Endocr Regul 2015;49(2): 84-90.
Bozkurt NC, Karbek B, Ucan B, et al. Endocrine Pract 2013;19(3): 479-484. https://doi.org/10.4158/EP12376.OR.
Zamurdan OM, Diрer E, Bideci A, et al. J Pediatr Endocrinol Metab 2012; 25 (5-6): 467-470. https://doi.org/10.1515/jpem-2012-0021.
van Belle TL, Gysemans C, Mathieu C. Trends Endocrinol Metab 2013;24(11): 561-568. https://doi.org/10.1016/j.tem.2013.07.002.
Song Y, Wang L, Pittas AG, et al. Diabetes Care 2013; 36 (5): 1422-1428. https://doi.org/10.2337/dc12-0962.
von Restorff C, Bischoff-Ferrari HA, Theiler R. Bone 2009; 45: 747-749.
Grammatiki M, Karras S, Kotsa K. Hormones (Athens) 2018. https://doi.org/10.1007/s42000-018-0063-z.